Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Autolus Therapeutics (AUTL) has issued an announcement.
Autolus Therapeutics plc recently announced promising updates on their pivotal FELIX study of obecabtagene autoleucel, a potential treatment for relapsed/refractory adult B-cell Acute Lymphoblastic Leukemia, at the ASCO Annual Meeting. Following this, they conducted a conference call and webcast to delve into the data, engaging the investment community with insights into the study’s longer-term outcomes and additional analyses. The presented information, though not filed under SEC regulations, is a significant stride in the company’s communication with its stakeholders.
For an in-depth examination of AUTL stock, go to TipRanks’ Stock Analysis page.